发布求助
文献互助 智能选刊 最新文献

Biotechnology healthcare最新文献

筛选
英文 中文
Serious games. 严肃游戏。
Biotechnology healthcare Pub Date : 2011-01-01
Katherine T Adams
{"title":"Serious games.","authors":"Katherine T Adams","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086131/pdf/bth08_1p001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30555140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New tests can identify the genetic mutations that drive lung cancers. 新的测试可以识别导致肺癌的基因突变。
Biotechnology healthcare Pub Date : 2011-01-01
Bob Carlson
{"title":"New tests can identify the genetic mutations that drive lung cancers.","authors":"Bob Carlson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 1","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086125/pdf/bth08_1p008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30555142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulators place spotlight on drug prices. 监管机构将重点放在药品价格上。
Biotechnology healthcare Pub Date : 2011-01-01
John Carroll
{"title":"Regulators place spotlight on drug prices.","authors":"John Carroll","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 2","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138386/pdf/bth08_2p008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30555150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The biologic finance and access council 2nd annual biologics healthcare survey: views from key healthcare stakeholders. 生物金融和准入委员会第二次年度生物制剂医疗保健调查:来自主要医疗保健利益相关者的观点。
Biotechnology healthcare Pub Date : 2011-01-01
David B Nash, Michael Toscani, F Randy Vogenberg
{"title":"The biologic finance and access council 2nd annual biologics healthcare survey: views from key healthcare stakeholders.","authors":"David B Nash,&nbsp;Michael Toscani,&nbsp;F Randy Vogenberg","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Although biologics are a growing area of interest, payers, purchasers, and providers understand surprisingly little about their overall costs or benefits coverage.</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 2","pages":"19-21"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138381/pdf/bth08_2p019.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30555153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Putting a lid on chemotherapy costs. 限制化疗费用。
Biotechnology healthcare Pub Date : 2011-01-01
Bob Carlson
{"title":"Putting a lid on chemotherapy costs.","authors":"Bob Carlson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Genomic Health's Oncotype DX Colon Cancer Assay assesses the risk of stage II colon cancer recurrence and potential adjuvant chemotherapy benefit. Cost savings could be huge.</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 2","pages":"15-8"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138387/pdf/bth08_2p015.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30555152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Everyone wants in, but with no ground rules, the biosimilar business remains elusive. 每个人都想进入，但由于没有基本规则，生物仿制药行业仍然难以捉摸。
Biotechnology healthcare Pub Date : 2011-01-01
John Carroll
{"title":"Everyone wants in, but with no ground rules, the biosimilar business remains elusive.","authors":"John Carroll","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 3","pages":"12-3"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278118/pdf/bh0803012.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30553396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Talking to Different Audiences: Mini-Sentinel, precursor to the FDA's long-awaited Sentinel drug safety surveillance system, may soon reap benefits for insurers and patients. 面向不同受众:Mini-Sentinel是FDA期待已久的Sentinel药物安全监测系统的前身，可能很快就会为保险公司和患者带来好处。
Biotechnology healthcare Pub Date : 2011-01-01
John Carroll
{"title":"Talking to Different Audiences: Mini-Sentinel, precursor to the FDA's long-awaited Sentinel drug safety surveillance system, may soon reap benefits for insurers and patients.","authors":"John Carroll","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 4","pages":"4-5"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278129/pdf/bh0804004.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30553407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why Bigger Is Better For Controlling Oncology Spend: It offers less competition - perhaps - but can be a boon for evidence-based pathway initiatives. 为什么规模越大越有利于控制肿瘤支出:它可能带来较少的竞争，但对循证途径倡议来说可能是一个福音。
Biotechnology healthcare Pub Date : 2011-01-01
John Carroll
{"title":"Why Bigger Is Better For Controlling Oncology Spend: It offers less competition - perhaps - but can be a boon for evidence-based pathway initiatives.","authors":"John Carroll","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Oncology practices nationwide face rising maintenance costs and lower reimbursements for biologic therapies. It's even tougher for small community-based practices, which often lag in adopting new standards of cancer care. Group purchasing organizations claim they have the market clout that oncologists need, and McKesson is betting that they are right. Will the US Oncology buyout deliver?</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 1","pages":"17-21"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086127/pdf/bth08_1p017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30555144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lots of enthusiasm, lots of questions. 很多热情，很多问题。
Biotechnology healthcare Pub Date : 2011-01-01
Michael D Dalzell
{"title":"Lots of enthusiasm, lots of questions.","authors":"Michael D Dalzell","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Value-based benefit design is all the rage, but applying it to biologics is complicated. Several issues must be addressed if VBBD is to rule this frontier.</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 2","pages":"10-4"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138390/pdf/bth08_2p010.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30555151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intervening on behalf of patients. 代表病人进行干预。
Biotechnology healthcare Pub Date : 2011-01-01
Bob Carlson
{"title":"Intervening on behalf of patients.","authors":"Bob Carlson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Adherence to a biologic treatment regimen is essential for tracking efficacy and justifying its cost. That's where medication therapy management services come in.Pharmacists are providing medication therapy management (MTM) services for patients taking biologics, although studies to demonstrate its cost-effectiveness are lacking. Is this the best way to ensure that high-cost, high-impact biologics are used correctly?</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 1","pages":"10-5"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086129/pdf/bth08_1p010.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30555143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信